Optimizing Bispecific Antibody Treatment for Non-Hodgkin Lymphoma: Current Best Practices for Mitigating and Managing Cytokine Release Syndrome
Released On
September 22, 2025
Expires On
March 22, 2026
Media Type
Internet
Estimated Time to Complete Activity
90 minutes
Specialty
Hematology & Oncology, Pharmacy
Topics
Lymphoma, Non-Hodgkin Lymphoma (NHL)
Providers/Grant Support
Jointly provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).
This activity is supported by an independent educational grant from Genentech.
Credit Available
- Nurses - 1.5 Contact Hours
- Pharmacists - 1.5 Contact Hours (provided by Postgraduate Healthcare Education (PowerPak) [PHARMACISTS: PLEASE GO TO POWERPAK at https://www.powerpak.com/course/preamble/126830 TO COMPLETE THIS LESSON AND CLAIM CREDIT.]
Target Audience
This activity is designed to meet the educational needs of oncology pharmacists, nurse practitioners (NPs), and nurses.
Program Overview
The goal of this educational activity is to equip and empower oncology pharmacists, nurse practitioners (NPs), and nurses with the knowledge, competence, and confidence they need to ensure the safe and effective use of bispecific antibodies (BsAbs) for patients with B-cell non-Hodgkin lymphoma, with a particular emphasis on best practice monitoring, mitigation, and collaborative management of BsAb-associated cytokine release syndrome within integrated clinical workflows and logistical frameworks.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the prevalence, practice gaps, and traditional standard of care treatment for B-cell non-Hodgkin lymphoma (B-NHL)
- Evaluate the trial evidence and regulatory milestones for CD3xCD20 bispecific antibodies (BsAbs) in B-NHL, with a focus on BsAb-associated cytokine release syndrome (CRS)
- Design coordinated care plans to monitor, mitigate, and manage CRS, ICANS, and late toxicities in patients receiving BsAbs for B-NHL in accordance with current expert consensus guidance
Faculty
Issam S. Hamadeh, PharmD
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center,
New York, NY
Katherine Byar, MSN, APN, BC, BMTCN®
Hematological Malignancy Nurse Practitioner
Oncology/Hematology
Fred & Pamela Buffett Cancer Center
Omaha, NE
Accreditation Statements
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-25-045-H01-P
Credits: 1.5 hours (0.15 ceu)
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosures of Conflicts of Interest
Dr. Hamadeh has disclosed no actual or potential conflicts of interest in relation to this program.
Ms. Byar has disclosed that she has received royalties from ONS and Springer Publishing for textbook editing and other financial/material support from APSHO Case-based Learning as a content contributor.
The clinical reviewer, Megan May, PharmD, BCOP has disclosed that she receives non-CME honoraria from Amgen and Astra Zeneca.
Susanne Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.
The PIM planners and others have nothing to disclose.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
Pharmacists, please go to https://www.powerpak.com/course/preamble/126830 to complete this lesson and claim credit.
Nurse, there are no fees for participating and receiving CE credit for this enduring activity. To receive CE credit participants must:
- Read the CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available for the participant.
Disclosure of Unlabled Use
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Genentech. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.
Contact Information
For CME questions please contact: [email protected]